drugset / Trial / NCT06047977
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Phase 1
Recruiting
30 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Benjamin Gilkey Fund · collabCannonball Kids' Cancer Foundation · collabSwim Across America · collab
NaSingle-groupOpen-labelTreatment
Summary
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors
Timeline
- Start
- 2025-06-02
- Primary completion
- 2029-09-01
- Completion
- 2029-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |